Oct 19, 2023 / 05:30PM GMT
Operator
And with us is the CEO, Panna Sharma. Panna, you have the floor.
Panna Sharma - Lantern Pharma, Inc. - CEO, President, and Director
Thank you. Thank you, everyone, for attending. I'm going to talk a little bit about Lantern Pharma, but I'm going to spend quite a bit of time talking about how we use artificial intelligence to develop cancer medicines that are, hopefully, faster to develop, derisked in the development process, and can get to patients much more rapidly. We are a public company. I will make some forward-looking statements that we may or may not update. We're traded on NASDAQ, ticker LTRN.
Today, we have 13 lead drug programs that are powered by AI. We had three when we went public, would think back in June of 2020. So we've been really developing quite a few programs. We have five programs that are now in the clinical stage. 48 million in cash, over 95 patents. It takes us about 2.5 years to get a new molecule into a first-in-human Phase 1 trial. And the average cost per programs in early stages is only about $1.5 million. These are unheard
Lantern Pharma Inc at ThinkEquity Conference Transcript
Oct 19, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers